Sandoz Group AG (LTS:0SAN) Common Stock : CHF22 Mil (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Common Stock?

Sandoz Group AG's quarterly common stock increased from Dec. 2023 (CHF21 Mil) to Jun. 2024 (CHF21 Mil) and increased from Jun. 2024 (CHF21 Mil) to Dec. 2024 (CHF22 Mil).

Sandoz Group AG's annual common stock declined from Dec. 2022 (CHF8,150 Mil) to Dec. 2023 (CHF21 Mil) but then increased from Dec. 2023 (CHF21 Mil) to Dec. 2024 (CHF22 Mil).

Sandoz Group AG Common Stock Historical Data

The historical data trend for Sandoz Group AG's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG Common Stock Chart

Sandoz Group AG Annual Data

Trend

Dec22

Dec23

Dec24

Common Stock

8,149.64

20.76

22.29

Sandoz Group AG Semi-Annual Data
	Dec22	Jun23	Dec23	Jun24	Dec24
Common Stock	8,149.64	-	20.76	21.45	22.29

Sandoz Group AG Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Sandoz Group AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (LTS:0SAN) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

SDZXF:USA SDZNY:USA SDZz:UK D8Y0:Germany SDZ:Switzerland

Address

Centralbahnstrasse 4, Basel, CHE, 4051

Website

https://www.sandoz.com

Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as the first US biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in its pipeline.

Sandoz Group AG Headlines

No Headlines